US-based pre-clinical and clinical laboratory services provider Charles River Laboratories International has extended its drug discovery alliance with Roche Group’s Genentech.

As part of the integrated alliance, Charles River will provide early discovery services including medicinal chemistry, in vitro and in vivo biology, structural biology, and computer-aided drug design to Genentech.

These services will help Genentech identify promising candidates for preclinical development.

"We are proud to work with Genentech to identify early-stage molecules that will ultimately result in innovative treatments."

Charles River Laboratories International Integrated Drug Discovery executive director John Montana said: “We are proud to work with Genentech to identify early-stage molecules that will ultimately result in innovative treatments for patients.

“Our long-term collaboration with Genentech has been mutually beneficial for both companies. As our teams have demonstrated, when biotechs and CROs work together, they have the ability to enhance innovations in early discovery research.”

Charles River and Genentech have engaged in an ongoing programme since 2005. The latest extension of the drug discovery alliance will allow the programme to continue for another three years.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Starting with a single project involving medicinal chemistry, the programme has evolved over the past 11 years to a multi-disciplinary collaboration.

Global pharmaceutical and biotechnology companies, government agencies, and academic institutions use Charles River’s products and services to accelerate their research and drug development efforts.